投资
77年投资退出
21关于Lundbeckfond合资企业
Lundbeckfond合资企业是一个生命科学风险基金投资于生命科学公司主要在欧洲。Lundbeckfond主要投资于后期药物发现和开发,医学技术和诊断。他们的投资重点是在制药和生物制药,医学技术和诊断。他们将主要投资在临床前和临床早期项目和公司和专业制药领域特别感兴趣。他们还将投资于医学技术机会与原型开发和测试,以及诊断。Lundbeckfond也开放给所有治疗领域的机会。该基金的主要焦点是欧洲,但他们将有选择地参与投资在美国通过他们的网络。Lundbeckfond将导致投资者在欧洲北部的角色。
想告知投资者类似Lundbeckfond合资企业关于你的公司吗?
提交你的分析师简报在投资者面前,CB Insights的平台上的客户和合作伙伴。德赢体育vwin官方网站
最新的Lundbeckfond合资企业新闻
2018年8月5日,
16:18 5美国东部时间2018年8月| BioPortfolio Lundbeckfond企业Lundbeckfond报告总结,以前LFI生命科学投资的子公司Lundbeck公司基础上,它是一家金融服务提供商,提供风险和发展股权投资、股权资本的扩张,并购和收购。公司投资lifescience,制药、生物制药和医学技术公司。它也投资于临床项目,各种治疗领域和药物开发。Lundbeckfond投资在各个项目进行项目可行性分析。公司投资于生命科学公司生成返回继续支持该组织的活动。它是在美国。Lundbeckfond总部位于丹麦哥本哈根。Lundbeckfond企业药品医疗交易和联盟为您提供全面的数据和趋势分析公司并购的MAs,伙伴关系和融资。报告提供详细信息的并购,股票/债券发行、私募股权、风险融资和合作公司交易记录的一个五年计划。报告提出了详细的比较数据,交易数量和他们的价值分为交易类型,界别分组和地区。 GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News
Lundbeckfond企业投资
77年投资
Lundbeckfond冒险了77年投资。他们最新的投资IO生物技术作为他们的一部分管,二世在2023年8月8日。
Lundbeckfond企业投资活动
日期 |
轮 |
公司 |
量 |
新的吗? |
共同投资者 |
来源 |
---|---|---|---|---|---|---|
8/7/2023 |
管,二世 |
IO生物技术 |
75美元 |
没有 |
2 |
|
5/25/2023 |
B - II系列 |
VarmX |
32.16美元 |
没有 |
2 |
|
9/9/2021 |
B系列 |
LEXEO疗法 |
100美元 |
是的 |
9 |
|
5/5/2021 |
一个系列 |
|||||
3/22/2021 |
E系列 |
日期 |
8/7/2023 |
5/25/2023 |
9/9/2021 |
5/5/2021 |
3/22/2021 |
---|---|---|---|---|---|
轮 |
管,二世 |
B - II系列 |
B系列 |
一个系列 |
E系列 |
公司 |
IO生物技术 |
VarmX |
LEXEO疗法 |
||
量 |
75美元 |
32.16美元 |
100美元 |
||
新的吗? |
没有 |
没有 |
是的 |
||
共同投资者 |
|||||
来源 |
2 |
2 |
9 |
Lundbeckfond合资企业投资退出
21组合退出
Lundbeckfond合资企业有21投资组合出口。他们最新的投资退出Sanifit 在2021年11月22日。
日期 |
退出 |
公司 |
估值
提交的估值公司,采自国家申请或者新闻,由VentureSource的提供,或基于比较数据的估值模型。
|
收购者 |
来源 |
---|---|---|---|---|---|
11/22/2021 |
收购了 |
6 |
|||
11/5/2021 |
首次公开募股 |
公共 |
12 |
||
10/29/2021 |
首次公开募股 |
公共 |
9 |
||
Lundbeckfond合资企业团队
4团队成员
Lundbeckfond合资企业有4 团队成员,包括当前的管理合伙人,Mette社会阿格尔。
的名字 |
工作经历 |
标题 |
状态 |
---|---|---|---|
Mette社会阿格 |
|
管理合伙人 |
当前的 |
的名字 |
Mette社会阿格 |
|||
---|---|---|---|---|
工作经历 |
|
|||
标题 |
管理合伙人 |
|||
状态 |
当前的 |